Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 11705841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular targeting and antigen presentation

  2001cited by this paper
• Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.

  2001cited by this paper
• Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

  2001cited by this paper
• Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

  2001cited by this paper
• Activity of thalidomide in AIDS-related Kaposi's sarcoma.

  2000cited by this paper
• Thalidomide: a comeback?

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Chemotherapeutic drugs—more really is not better

  2000cited by this paper
• Angiogenesis and cancer metastasis.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice.

  2000cited by this paper
• Phase II evaluation of thalidomide in patients with metastatic breast cancer.

  2000cited by this paper
• Genes expressed in human tumor endothelium.

  2000cited by this paper
• Thalidomide: current and potential clinical applications.

  2000influential reference
• Thalidomide on the comeback trail

  1999cited by this paper
• Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

  1999cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

  1998cited by this paper
• Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.

  1998cited by this paper
• Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

  1996cited by this paper
• Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)

  1996cited by this paper
• Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.

  1995cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study

  1994cited by this paper
• ALTERATIONS IN THE

  1985cited by this paper
• Further observation with thalidomide in lepra reactions.

  1965cited by this paper
• Progress under the Kefauver-Harris Drug Amendments.

  1964cited by this paper
• Progress under the Kefauver-Harris Drug Amendments.

  1964cited by this paper

• Novel oxalamide derivatives for COXs expression and breast cancer: design, synthesis, biological evaluation, and docking studies

  2023cites this paper
• Symmetrical and un-symmetrical curcumin analogues as selective COX-1 and COX-2 inhibitor.

  2021cites this paper
• The effect of thalidomide on cachexia in upper gastrointestinal cancer

  2015cites this paper
• Synthesis, biological activity screening and molecular modeling study of acylaminoacetamide derivatives

  2015influential citation
• Targeting tumour vasculature as a cancer treatment

  2007influential citation
• Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors.

  2007cites this paper
• Effect of placental fatty acid metabolism and regulation by peroxisome proliferator activated receptor on pregnancy and fetal outcomes.

  2007cites this paper
• Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors.

  2006cites this paper
• utrition and Metabolism in Kidney Disease

  2006cites this paper
• Nutrition and metabolism in kidney disease.

  2006cites this paper
• Novel agents that potentially inhibit irinotecan-induced diarrhea.

  2005cites this paper
• Expression of cyclooxygenase isoforms in developing rat placenta, human term placenta, and BeWo human trophoblast model.

  2005cites this paper
• Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide.

  2005cites this paper
• Metronomic low‐dose chemotherapy as antiangiogenic therapeutic strategy for cancer

  2005cites this paper
• Anti-angiogenic gene therapy for cancer (review).

  2004cites this paper
• Antiangiogenic strategies, compounds, and early clinical results in breast cancer.

  2004cites this paper
• N-phenylphthalimide-type cyclooxygenase (COX) inhibitors derived from thalidomide: substituent effects on subtype selectivity.

  2004cites this paper
• A Mechanistic Perspective on the Specificity and Extent of COX-2 Inhibition in Pregnancy

  2004cites this paper
• Cyclooxygenase inhibitors derived from thalidomide.

  2003cites this paper
• Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

  2003cites this paper
• Anti-tumor activity of the novel angiogenesis inhibitor anginex.

  2003cites this paper
• Review Articles: Uremic Malnutrition: New Insights Into an Old Problem

  2003cites this paper
• Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer

  2003cites this paper
• Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.

  2002cites this paper
• Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

  2002cites this paper